The Cardiovascular Markers Copeptin and High-sensitive C-reactive Protein Decrease Following Specific Therapy for Primary Aldosteronism

Abstract/Summary:

Copeptin and high-sensitive C-reactive protein (hsCRP) are biomarkers associated with increased mortality in patients with cardiovascular and cerebrovascular disease as well as in the general population. No data exist regarding these markers in patients with primary aldosteronism. A total of 113 primary aldosteronism patients (64% male) from two centers of the prospective German Conn’s Registry were identified, for whom a full data set and blood samples at baseline and follow-up (14 ± 3.4 months) after initiation of specific primary aldosteronism treatment were available. These cases were matched 1 : 3 (n = 339) for sex, renal function, BMI, age and SBP with participants from the Cooperative Health Research in the Region of Augsburg F4 survey. Copeptin and hsCRP were determined by sandwich fluoroimmunoassay. Copeptin and hsCRP levels decrease following specific primary aldosteronism therapy reflecting successful cardiovascular risk reduction. However, they are no independent predictors regarding cure of primary aldosteronism.

Authors: Remde Hanna, Dietz Anna, Emeny Rebecca, Riester Anna, Peters Annette, de las Heras Gala Tonia, Then Cornelia, Seissler Jochen, Beuschlein Felix, Reincke Martin, Quinkler, Marcus
Keywords: C-reactive protein, copeptin, aldosteronism treatment outcome
DOI Number: 10.1097/HJH.0000000000001041      Publication Year: 2016

To search for other research papers by topic, keyword, author, or year, please go to our Publications page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.